Anti-HIV Agent
AssigneeFuso Pharmaceutical Industries, Ltd.
InventorsNobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.
Claims23
1-18. (canceled)
A method for evaluating an anti-HIV activity of MBP, comprising:
- (a) culturing a first mixed system including HIV and MBP;
- (b) culturing a second mixed system including target cells and MBP;
- (c) preparing infected cells by combining said first mixed system and second mixed system;
- (d) culturing the infected cells;
- (e) preparing clean cells by washing the infected cells;
- (f) culturing the clean cells;
- and
- (g) evaluating anti-HIV activity of the MBP by measuring HIV virus in the culture supernatant, wherein anti-HIV activity of MBP is indicated by reduction in the measurable HIV virus in the culture supernatant, compared to a control culture.
25-27. (canceled)
The method according to claim 49, wherein said recombinant epidemic strain is CRF01_AE.
The method according to claim 18, wherein said HIV is a CCR5-tropic virus.
The method according to claim 18, wherein said HIV is a CXCR4-tropic virus.
The method according to claim 18, wherein said HIV is a CCR5/CXCR4-tropic virus.
The method according to claim 18, wherein said HIV is a macrophage-tropic virus.
The method according to claim 18, wherein said HIV is a T-cell-tropic virus.
The method according to claim 18, wherein said HIV is a macrophage/T-cell-tropic virus.
39-40. (canceled)
Dependencies are inferred from the claim text.